Navigation Links
ACUSON CV70

ProductsACUSON CV70
Company Siemens Medical Solutions USA, Inc.
Item ACUSON CV70
Features 
  • Expanded cardiac calculations
  • Axius Edge-Assisted Ejection Fraction
  • Spectral DTI Doppler tissue imaging capability with quantification
  • A digital stress echo package
  • A broad family of transducers for adult, pediatric, fetal echo, transesophageal and intraoperative applications
  • V5Ms TEE compatibility across platforms
Description The new ACUSON CV70 cardiovascular ultrasound system provides dedicated and complete cardiovascular capabilities in a powerful, all-digital ultrasound system offering exceptional image quality, Doppler sensitivity, color flow sensitivity and spatial resolution everything you associate with the ACUSON family of cardiovascular products. Designed specifically for busy cardiovascular specialists, the CV70 system includes a comprehensive spectrum of high-quality, high-performance features for full functionality on demand.
Info Siemens Medical Solutions USA, Inc.
Customer Service: (888) 826-9702
Web site: http://www.usa.siemens.com/medical

Related medicine products :

1. ACUSON Antares
2. ACUSON Sequoia C512 Echocardiography System
3. ACUSON Cypress cardiovascular system PLUS
TAG: ACUSON
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products:
(Date:5/15/2008)...al of tailoring cancer treatment for each individu...enter today presented a study suggesting a simple ...reatment efficacy for patients with metastatic bre...times months to determine if a particular cancer t...to observe any significant radiographic changes in...
(Date:5/15/2008)...Newswire-FirstCall/ -- Digital Power,Corporation (...ced its,financial results for the first quarter en...ue of $3,169,000 for the quarter ended,March 31, 2...same quarter,last year. An operating loss of $165,...mpared to an operating profit of $25,000 for the s...
(Date:5/15/2008)...15 /PRNewswire-FirstCall/ -- Alexza,Pharmaceutical...os A. Parra,has joined the company as Vice Preside...development and execution of quality program,strat...eclinical / clinical,product candidates. Mr. Parra...Quality at Telik, Inc. in Palo Alto, California, w...
(Date:5/15/2008)...15 /PRNewswire/ -- Congresswoman Lois Capps,(D-CA)...mmittee organized a,briefing for key staff members...n to ban asbestos., WHEN: Monday, May 19th at 2...218 List of discussants includes Mary Hesdorffer,...the Mesothelioma Applied Research Foundation, who,...
Breaking Medicine News(10 mins):Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3Health News:Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality 2
..., which can be likened to about two to four drinks...ay actually be a way to live// longer. While moder... risk of death, Italian researchers have said. Re... should be urged to cut their consumption, but peo...
...trial chemicals in the environment can damage the ...l disorders (NDDs)—autism,// attention deficit dis... has been insufficient research done to identify t...e injury to the developing brains of children. In...
Testosterone Decline in Men Linked to Lifestyle, Increases in Obese Girls
...e of the toughest and most strenuous jobs. A Canad...that the workload// and strain makes them sick. T... 2006 on nearly 19,000 nurses, which included regi...ctical nurses and registered psychiatric nurses. ...
Other Medicine News:Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 2Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 3Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 4Health News:Testosterone Decline in Men Linked to Lifestyle, Increases in Obese Girls 2
(Date:5/15/2008)...a newly cleared device to identify the, lipid cor...sociated with complications of c...wswire/ -- InfraReDx, Inc. today,announced that ph... have,successfully used its LipiScan(TM) Coronary ...atheterization. This is the first patient in the,w...
(Date:5/15/2008)...ire-FirstCall/ -- Novavax, Inc. (Nasdaq:,NVAX) tod...he Phase I/IIa,study of its pandemic influenza vac...ts. Favorable interim results from the first phase...0 healthy adult volunteers, were,reported in Decem...vaccine,is well tolerated and immunogenic at the 1...
(Date:5/15/2008)...ual Meeting of The American Society of ...IRVINE, Calif., May 15 /- I...ay announced the presentation of updated data,from...tide (L-MTP-PE) in,patients with lung metastases a...are and often fatal bone tumor that typically affe...
(Date:5/14/2008)...rtant for cervical cancer prevention, GRAZ, Austr... an,extended follow-up study show that GlaxoSmithK...ne, CERVARIX(R) generates sustained high levels of...on cervical cancer-causing,human papillomavirus ty...ion of sustained neutralizing antibody levels obse...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6Californias Historic RN to Patient Hospital Staffing Ratios Upgraded Again With New Year 8998 1Californias Historic RN to Patient Hospital Staffing Ratios Upgraded Again With New Year 8998 2Californias Historic RN to Patient Hospital Staffing Ratios Upgraded Again With New Year 8998 3Sanofi Pasteur Enters Agreement With Crucell for Next Generation Biologicals Against Rabies 8995 1Sanofi Pasteur Enters Agreement With Crucell for Next Generation Biologicals Against Rabies 8995 2Sanofi Pasteur Enters Agreement With Crucell for Next Generation Biologicals Against Rabies 8995 3Sanofi Pasteur Enters Agreement With Crucell for Next Generation Biologicals Against Rabies 8995 4Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference 2415 1Nektar Therapeutics President and CEO Howard W Robin to Present At JPMorgan 26th Annual Healthcare Conference 2412 1
...opean Association for the Study,of the Liver, PRIN...sset,announced today that presentations of preclin...atitis B (HBV) and PSI-6130, the,parent molecule o...ll be made during the 42nd Annual Meeting of the E...SL) being held in,Barcelona, Spain from April 11-1...
...d at ECCMID/ICC, MUNICH, Germany, April 03, 2007 /...ed results from two studies showing the,improved p...vitro,when tested with a common wetting agent (pol...ity of oritavancin against S.,pneumoniae in a mous...copeptide antibiotic, is Targanta,s lead product c...
Other Medicine Technology:Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL 2Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL 3Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6